Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8106606 | 0.90 | GLP1R (0.39) | GLP1RALBFOLH1LMNASMN1; SMN2 | |
| SCHEMBL12147683 | 0.86 | GLP1R (0.36) | GLP1RALBFOLH1LMNASMN1; SMN2 | |
| SCHEMBL14500495 | 0.86 | ALB (0.43) | GLP1RALBFOLH1SIRT5 | |
| SCHEMBL8107176 | 0.84 | GLP1R (0.48) | GLP1RALBFOLH1SIRT5 | |
| SCHEMBL12743556 | 0.83 | GLP1R (0.38) | GLP1RFOLH1LMNASMN1; SMN2 | |
| SCHEMBL12743650 | 0.78 | GLP1R (0.48) | GLP1RALB | |
| SCHEMBL8122831 | 0.78 | GLP1R (0.48) | GLP1RALB | |
| SCHEMBL14500436 | 0.76 | GLP1R (0.48) | GLP1RALBSIRT5 | |
| SCHEMBL14500437 | 0.76 | GLP1R (0.48) | GLP1RALBSIRT5 | |
| SCHEMBL14500432 | 0.75 | GLP1R (0.56) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211240-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-01 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GLP1R 4619/4885ALB 1656/4885FOLH1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.